Table 3:

Relationship between mechanistic endpoints and composite endpoint

Mechanistic Assays	All Subjects (N=61) n (%)	Composite Endpoint Yes (N=28) n (%)	Composite Endpoint No (N=33) n (%)	P-value
Pre to Post-Transplant Antibody Status
Collagen V
Neg to Neg	10(16.4)	7(25.0)	3( 9.1)	0.135
Neg to Pos	21(34.4)	8(28.6)	13(39.4)
Ka1Tubulin
Neg to Neg	3( 4.9)	2( 7.1)	1( 3.0)	0.553
Neg to Pos	26(42.6)	10(35.7)	16(48.5)
Donor Specific Antibody
Neg to Neg	28(45.9)	11(39.3)	17(51.5)	0.420
Neg to Pos	28(45.9)	14(50.0)	14(42.4)
Post-Transplant Antibody Status
ELISA: Auto Antibodies
Collagen V
Positive	46(75.4)	17(60.7)	29(87.9)	0.038
Negative	13(21.3)	9(32.1)	4(12.1)
Missing	2( 3.3)	2( 7.1)	0	NA
Ka1Tubulin
Positive	56(91.8)	24(85.7)	32(97.0)	0.578
Negative	3( 4.9)	2( 7.1)	1( 3.0)
Missing	2( 3.3)	2( 7.1)	0	NA
Anti-HLA Antibodies
Class I
Positive	33(54.1)	12(42.9)	21(63.6)	0.179
Negative	26(42.6)	14(50.0)	12(36.4)
Missing	2( 3.3)	2( 7.1)	0	NA
Class II
Positive	31(50.8)	13(46.4)	18(54.5)	0.728
Negative	28(45.9)	13(46.4)	15(45.5)
Missing	2( 3.3)	2( 7.1)	0	NA
Donor Specific Antibody
Yes	30(49.2)	14(50.0)	16(48.5)	0.795
No	30(49.2)	13(46.4)	17(51.5)
ELISPOT
Pre to Post-Transplant ELISPOT Status
Donor Specific ELISPOT (>=25)
Neg to Neg	19(31.1)	10(35.7)	9(27.3)	0.433
Neg to Pos	10(16.4)	3(10.7)	7(21.2)
Kα1T Specific ELISPOT (>=5)
Neg to Neg	3( 4.9)	1( 3.6)	2( 6.1)	>0.999
Neg to Pos	20(32.8)	9(32.1)	11(33.3)
Post-transplant Donor Specific ELISPOT (>=25)
Positive	16(26.2)	6(21.4)	10(30.3)	0.368
Negative	21(34.4)	11(39.3)	10(30.3)
Post-transplant Kα1T Specific ELISPOT (>=5)
Positive	52(85.2)	22(78.6)	30(90.9)	>0.999
Negative	6( 9.8)	3(10.7)	3( 9.1)